Development and Validation of a new Reversed-phase HPLC Method for the Determination of Ezetimibe in Pharmaceutical Dosage forms
1,2, 1, 2, 3
- 1Ecron Acunova Manipal Acunova Clinical Research Centre, 4th Floor, Shirdi Sai Baba Cancer Hospital, Manipal - 576104, Karnataka.
- 2Department of Pharmaceutical Chemistry Manipal University, Manipal. edu, Madhav Nagar, Manipal - 576104, Karnataka.
- 3Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune - 412207.
CORRESPONDENCE
Ghanshyam Panjwani
Analytical Department, Ranbaxy Laboratories Ltd., R and D, Sarhul, Sector-18, Gurgaon - 122015, Haryana
Received: 16-03-2012; Accepted: 02-01-2013.
Volume 47, Issue 1 · pp. 7-12 · 2013 · DOI:
ABSTRACT
Ezetimibe belongs to a group of selective and very effective 2-azetidione cholesterol absorption inhibitors that act on the level of cholesterol entry into enterocytes. A new, rapid, specific reversed-phase HPLC method has been developed for assaying ezetimibe in pharmaceutical dosage forms. The assay involved an isocratic elution of ezetimibe in a Betasil C (250 mm x 4.6 mm i.d., 5μ) column using a mobile phase composition of 18 Acetonitrile: 10 mM Na HPO pH 7.0 (55:45 v/v). The flow rate was 1ml/min and the analyte monitored at 233nm. The assay method was found to 2 4 be linear from 4-24μg/mL. All the validation parameters were within the acceptance range. The developed method was successfully applied to estimate the amount of ezetimibe in tablets.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Panjwani, G., Shetty, R., Shenoy, G., & Dhamecha, D. (2013). Development and Validation of a new Reversed-phase HPLC Method for the Determination of Ezetimibe in Pharmaceutical Dosage forms. Indian Journal of Pharmaceutical Education and Research, 47(1), 7-12.
Copyright and licence
© 2013 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0